Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “modified”

433 pharma patents match "modified" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 433
Index total 30,257
Page 1 / 19

Quick answer

This filtered view shows 433 pharmaceutical patents matching "modified" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

433 results for “modified” · 30,257 patents in full index Clear search

  1. US 12414963

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Northwestern University · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  2. US 12410209

    Modified glucocorticoids

    The Board of Regents of the University of Texas System · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  3. US 12402611

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  4. US 12385044

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  5. US 12385043

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  6. US 12378280

    Deoxynucleic guanidines (DNG)-modified oligonucleotides and methods of synthesizing deoxynucleic guanidine strands

    Northwestern University · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  7. US 12378553

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  8. US 12331307

    Modified immunization vectors

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  9. US 12331334

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  10. US 12317874

    Method of using a genetically modified mouse that expresses human albumin

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  11. US 12318418

    Modified adenoviruses

    University College Cardiff Consultants Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  12. US 12290573

    Modified RNAi agents

    Alnylam Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  13. US 12268688

    Compositions and methods of use for modified release minoxidil

    Veradermics Incorporated · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  14. US 12269801

    Modified amino acids

    Sutro Biopharma, Inc. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  15. US 12252552

    Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use

    Sutro Biopharma, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  16. US 12250931

    Genetically modified mouse with a humanized PNPLA3 gene and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  17. US 12226403

    Tebipenem pivoxil immediate and modified release oral dosage forms

    SPERO THERAPEUTICS, INC. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  18. US 12221622

    Modified pluripotent cells

    The Regents of the University of California · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  19. US 12215162

    BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

    The Board of Regents of the University of Texas System · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  20. US 12203072

    Chemically modified single-stranded rna-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  21. US 12173337

    Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  22. US 12173062

    Modified TNF-α antibodies and uses thereof

    Bright Peak Therapeutics AG · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  23. US 12168767

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  24. US 12161674

    CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted